saving the lives of liver disease patients





Our mission

Versantis is a preclinical stage pharmaceutical company focused on rare liver diseases. We are committed to the development of life-saving therapies for acute liver failure patients for which the current available care is not satisfactory.

A life-saving therapy

Versantis’ lead product candidate, VS-01, is the first safe and effective treatment for acute-on-chronic liver failure (ACLF), a life-threatening condition of high unmet medical need. The mortality of ACLF patients is alarming due to multi-organ failures resulting in a dangerous accumulation of toxins in the blood. The versatile mechanism of action of VS-01 can support simultaneously the affected organs (liver, kidneys, brain) and clear these toxins from the body.

discover the full potential of our pipeline...

News

Jul 2016
Versantis wins a Cydan scholarship!

Jun 2016
Japanese patent granted!

May 2016
VS-01 received the Orphan Drug Designation from the EMA! 

Versantis is selected for Mass Challenge 2016 Accelerator!

more news and more details...

 
 

Awards and supports

 

GET IN TOUCH

VISIT US

Versantis AG
c/o ETH Zurich
Otto-Stern-Weg 7, HPL D16.2
8093 Zurich

INFO


Copyright © 2016
Versantis AG